(December 10, 2015, 1:27 PM EST) -- WASHINGTON, D.C. — A pharmaceutical company on Nov. 13 petitioned the U.S. Supreme Court to consider an appellate court’s ruling rejecting its challenge to the way the U.S. Patent and Trademark Office (PTO) calculated patent term adjustments for two of its patents on treating dead tissue, saying the agency’s decision wasn’t unreasonable (Daiichi Sankyo Company, Ltd. v. Michelle K. Lee, Director, U.S. Patent and Trademark Office, No. 15-652, U.S. Sup.).

(Petition for writ of certiorari available. Document #78-151214-016B.)

Daiichi Sankyo Co. Ltd. sued PTO Director Michelle...